The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

A mutation that can undermine two-drug treatment with dolutegravir and lamivudine persists for at least 12 years in the ‘archive’ of HIV locked up in the DNA of blood cells in one in three people, ...

📢 With heavy hearts, we announce the proposed closure of our beloved charity, NAM aidsmap, this month. After 37 years of pioneering health journalism, community engagement, and empowerment through ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

A CRISPR-based gene-editing therapy called EBT-101 was safe and well tolerated but did not prevent viral rebound in three participants who stopped antiretroviral treatment in an early study, according ...

But even in the US, where CAB-LA is marketed as Apretude, it has been hard for injectable PrEP to establish a significant market . There have now been about 11,000 prescriptions in the two years since ...

In the same session, Dr Jenell Stewart of the Hennepin Healthcare Research Institute in Minneapolis, US argued that event-driven PrEP is demonstrably as effective as daily PrEP for gay men and trans ...

BHIVA recommends that people aged 40 and over should be offered a statin irrespective of lipid levels or estimated cardiovascular risk. People with HIV aged 40 and over with an estimated 10-year risk ...

In some cases, HIV can bypass the barrier that encases the brain and cerebrospinal fluid which can contribute to brain inflammation and neurocognitive symptoms. However, diagnosing this viral ‘escape’ ...

BnAbs eventually form in the bodies of about 15% of people with chronic HIV infection, by which time they are too late to be effective. We also know that there exists, somewhere in the immune system, ...